| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 175: 12-16 (1999)
© 1999 The Royal College of Psychiatrists
MF Poirier and P Boyer
SHU-Centre Hospitalier Sainte-Anne, Paris.
BACKGROUND: About one-third of patients fail to respond to initial antidepressant therapy, which suggests a need for more effective drugs. AIMS: To compare the efficacy and safety of venlafaxine and paroxetine in 122 patients with non-chronic treatment-resistant depression. METHOD: In-patients or out-patients satisfying DSM-III-R criteria for major depression in evolution for less than eight months, having a baseline HAM-D score > or = 18 and a HAM-D Item 3 score < 3 were eligible. Patients were required to have a history of resistance to two previous antidepressant treatments and a CGI improvement score of 3 at the beginning of treatment. Doses were adjusted to 200-300 mg/day for venlafaxine and 30-40 mg/day for paroxetine. RESULTS: For the observed- case analysis, the response rate was 51.9% for venlafaxine and 32.7% for paroxetine (P = 0.044), and a remission was achieved in 42.3% of venlafaxine-treated and 20.0% of paroxetine-treated patients (P = 0.01). The incidence of adverse effects was comparable between treatment groups. CONCLUSIONS: Venlafaxine showed some evidence of superiority to paroxetine in this difficult-to-treat patient population.
This article has been cited by other articles:
|
|
 |
|
  A. Qaseem, V. Snow, T. D. Denberg, M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 725 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 734 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Brent, G. Emslie, G. Clarke, K. D. Wagner, J. R. Asarnow, M. Keller, B. Vitiello, L. Ritz, S. Iyengar, K. Abebe, et al. Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial JAMA, February 27, 2008; 299(8): 901 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Taylor and J R. Scott Volte-faceon venlafaxine - reasons and reflections. J Psychopharmacol, September 1, 2006; 20(5): 597 - 601. [PDF]
|
|
|
|
 |
|
 M. Fava, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, J. E. Alpert, P. J. McGrath, M. E. Thase, D. Warden, M. Biggs, J. F. Luther, et al. A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report Am J Psychiatry, July 1, 2006; 163(7): 1161 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Rush, M. H. Trivedi, S. R. Wisniewski, J. W. Stewart, A. A. Nierenberg, M. E. Thase, L. Ritz, M. M. Biggs, D. Warden, J. F. Luther, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med., March 23, 2006; 354(12): 1231 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Fleck and E. Horwath Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice Psychiatr Serv, August 1, 2005; 56(8): 1005 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Trick, N. Stanley, U. Rigney, and I. Hindmarch A Double-Blind, Randomized, 26-Week Study Comparing the Cognitive and Psychomotor Effects and Efficacy of 75 mg (37.5 mg b.i.d.) Venlafaxine and 75 mg (25 mg Mane, 50 mg Nocte) Dothiepin in Elderly Patients with Moderate Major Depression Being Treated in General Practice J Psychopharmacol, June 1, 2004; 18(2): 205 - 214. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Baldwin and R. Wild Management of depression in later life Advan. Psychiatr. Treat., March 1, 2004; 10(2): 131 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Zarate Jr., J. L. Payne, J. Quiroz, J. Sporn, K. K. Denicoff, D. Luckenbaugh, D. S. Charney, and H. K. Manji An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression Am J Psychiatry, January 1, 2004; 161(1): 171 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Keller Past, Present, and Future Directions for Defining Optimal Treatment Outcome in Depression: Remission and Beyond JAMA, June 18, 2003; 289(23): 3152 - 3160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Thomas and D. Taylor Evaluating the relationship of high-dose venlafaxine prescribing to treatment-resistant depression Psychiatr. Bull., March 1, 2003; 27(3): 93 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Anderson Drug treatment of depression: reflections on the evidence Advan. Psychiatr. Treat., January 1, 2003; 9(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Gilmor, M. J. Owens, and C. B. Nemeroff Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine Am J Psychiatry, October 1, 2002; 159(10): 1702 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Szabo and P. Blier Effects of Serotonin (5-Hydroxytryptamine, 5-HT) Reuptake Inhibition Plus 5-HT2A Receptor Antagonism on the Firing Activity of Norepinephrine Neurons J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Brent and B. Birmaher Adolescent Depression N. Engl. J. Med., August 29, 2002; 347(9): 667 - 671. [Full Text] [PDF]
|
|
|
|
 |
|
 D. SMITH, C. DEMPSTER, J. GLANVILLE, N. FREEMANTLE, and I. ANDERSON Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis The British Journal of Psychiatry, May 1, 2002; 180(5): 396 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, A. Gobert, F. Lejeune, A. Newman-Tancredi, J.-M. Rivet, A. Auclair, and J.-L. Peglion S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 565 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. THASE, A. R. ENTSUAH, and R. L. RUDOLPH Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors The British Journal of Psychiatry, March 1, 2001; 178(3): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Martin Venlafaxine had higher response and remission rates than paroxetine in non-chronic treatment resistant depression Evid. Based Ment. Health, May 1, 2000; 3(2): 51 - 51. [Full Text]
|
|
|
|
|
|
S. Daniels and M.-F. Poirier Drug treatment for resistant depression The British Journal of Psychiatry, April 1, 2000; 176(4): 398 - 398. [Full Text] [PDF]
|
|
|
|
 |
|
 Treatment-Resistant Depression May Respond to Venlafaxine Journal Watch Psychiatry, September 1, 1999; 1999(901): 4 - 4. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
